BioVersys Works to Bring Antibiotic Resistance to an End | Zendy

Marcel Tigges | Zendy; Marc Gitzinger | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

BioVersys Works to Bring Antibiotic Resistance to an End

Author(s) -

Marcel Tigges,

Marc Gitzinger

Publication year - 2014

Publication title -

chimia international journal for chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.387

H-Index - 55

eISSN - 2673-2424

pISSN - 0009-4293

DOI - 10.2533/chimia.2014.888

Subject(s) - resistance (ecology) , order (exchange) , work (physics) , engineering ethics , management , sociology , public relations , engineering , political science , business , biology , mechanical engineering , economics , ecology , finance

BioVersys, founded in 2008, is working on bringing a technology for screening and for the development of 'transcriptional regulator inhibiting compounds' (TRICs) to patients in order to overcome antibiotic resistance. The co-founders share their view on what makes successful scientists pursue a career as start-up entrepreneurs rather than a classic academic career. They describe the history and milestones of their company, and how their everyday work differs from that of peers in an academic or industrial research setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research